We are live on ! Find out more
CGEM icon

Cullinan Therapeutics

113 hedge funds and large institutions have $376M invested in Cullinan Therapeutics in 2023 Q4 according to their latest regulatory filings, with 23 funds opening new positions, 45 increasing their positions, 24 reducing their positions, and 14 closing their positions.

New
Increased
Maintained
Reduced
Closed

88% more repeat investments, than reductions

Existing positions increased: 45 | Existing positions reduced: 24

64% more first-time investments, than exits

New positions opened: 23 | Existing positions closed: 14

50% more capital inflows, than outflows

Capital inflows: $60.3M | Capital outflows: $40.2M

7% more funds holding

Funds holding: 106 → 113 (+7)

0% more funds holding in top 10

Funds holding in top 10: 3 → 3 (0)

2.77% less ownership

Funds ownership: 88.93% → 86.16% (-2.8%)

12% less call options, than puts

Call options by funds: $97K | Put options by funds: $110K

Holders
113
Holders Change
+7
Holders Change %
+6.6%
% of All Funds
1.64%
Holding in Top 10
3
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.04%
New
23
Increased
45
Reduced
24
Closed
14
Calls
$97​K
Puts
$110​K
Net Calls
-⁠$13​K
Net Calls Change
+$467​K

CGEM Hedge Fund Activity: Q4 2023 in Review

113 of the 6,880 institutional investors tracked by Wall St. Rank reported a position in Cullinan Therapeutics (CGEM) for Q4 2023, worth a combined $376M — up 9.2% from $344M a quarter earlier.

Buyers outnumbered sellers: 23 funds opened new CGEM positions and 14 closed out — a net gain of 9 holders — while 45 added to existing stakes and 24 trimmed.

The largest buyer was Blue Owl Capital Holdings, opening a new position worth an estimated $30.3M. The largest seller was Adage Capital Partners, exiting entirely with an estimated $10.4M sold.

  • 113 institutional investors held Cullinan Therapeutics (CGEM) as of Q4 2023, up from 106 in Q3 2023.
  • Funds reported $376M of Cullinan Therapeutics stock for Q4 2023, up 9.2% quarter-over-quarter.
  • 23 funds opened new Cullinan Therapeutics positions in Q4 2023 and 14 closed out, a net change of +9 holders.
  • The largest Cullinan Therapeutics buyer in Q4 2023 was Blue Owl Capital Holdings, an estimated $30.3M added.
  • The largest Cullinan Therapeutics seller in Q4 2023 was Adage Capital Partners, an estimated $10.4M sold.

Based on aggregated 13F filings for Q4 2023.